The objective of this study is to estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcinoma (BR-PDAC) independently in response to neoadjuvant sequential therapy of combination nab-paclitaxel and gemcitabine followed by stereotactic body radiotherapy (SBRT). Pancreatic cancer begins in the tissues of your pancreas — an organ in your abdomen that lies horizontally behind the lower part of your stomach. Others find tumor cells and help kill them or carry tumor-killing substances to them. The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors. Does pancreas enzyme replacement (PERT) decrease weight loss and improve quality of life in patients with unresectable pancreatic cancer? Radiation therapy uses high-energy x-rays to kill tumor cells. The purpose of this study is to establish the safety of the triple combination of BXCL701, NKTR-214, and avelumab in patients with unresectable or metastatic pancreatic cancer. The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of the oral RAD51 inhibitor CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose for evaluation in these patients. The purpose of this study is to test the safety, tolerability and possible benefit of a drug called tofacitinib in patients with metastatic pancreas cancer when given combined with a standard chemotherapy drug called gemcitabine. The purpose of this study is to to evaluate the rate of overall survival (OS) at two years in patients with either borderline or locally advanced pancreatic cancer who receive electron beam intraoperative radiation therapy (IORT) following chemotherapy and radiation therapy. Drugs used in chemotherapy, such as fluorouracil, irinotecan hydrochloride, oxaliplatin, gemcitabine hydrochloride, and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Las dosis son limitadas. The purpose of this study is to prospectively assemble a cohort of subjects >50 and ≤85 years of age with New-onset Diabetes (NOD): Diabetes mellitus is a common condition which is defined by persistently high blood sugar levels. For many patients, clinical trials may be a potential option to access experimental and cutting edge therapy. Sirolimus and vismodegib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. A Phase 1b/2 randomized, open-label trial to evaluate the safety, tolerability, PK, and preliminary antitumor activity of immunotherapy-based treatment combinations in participants with metastatic pancreatic ductal adenocarcinoma. Clinical Trials Please contact your Abramson Cancer Center Oncologist about enrollment into a trial. Ethanol (alcohol) injection may treat cysts by killing the lining cells of the cyst, and is an accepted treatment for cysts of other organs. Imaging tests that create pictures of your internal organs. Cystic tumors of the pancreas are fluid-filled growths. BPM31510 Administered Intravenously With or Without Gemcitabine in Advanced Pancreatic Cancer Patients, A Study of LY2090314 and Chemotherapy in Participants with Metastatic Pancreatic Cancer, A Study to Analyze the Safety and Effectiveness of the NanoKnife® System in Unresectable Stage 3 Pancreatic Adenocarcinom Patients, Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates, Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients with Pancreatic Cancer That Has Been Removed by Surgery, High-Dose Radiation Therapy Versus Standard Care in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery, Pharmacokinetic and Safety Study of Nab ®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects with Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubenemia, A Study to Evaluate Binimetinib in Combination with Encorafenib in Patients with Pancreatic Malignancies and a Somatic BRAFV600E Mutation, A Study to Evaluate the Diagnostic Potential of a Lateral Flow Assay to Detect QSOX1 Peptide in Patients With or At Risk for Pancreatic Cancer, Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202), Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma, Evaluating FDG PET-MRI-based Biomarkers in Borderline Resectable Pancreatic Cancer, A Study of ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Pancreatic Cancer, International Multicenter Registry of Cancer of the Pancreas Screening, Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer, Gemcitabine Hydrochloride in Treating Patients with Locally Advanced Pancreatic Cancer, A Study of BBI608 Combined with Standard Chemotherapies in Adult Patients who have Pancreatic Cancer, PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer, A Study to Increase Understanding About Pancreatic Cancer Genetics and Response to Drug Therapy, A Study to Evaluate BXCL701 Combined with PD-L1 Mab Avelumab (Bavencio) and Bempegaldesleukin (NKTR-214) in Patients with Currently, there is no test to identify the small number of patients who have diabetes caused by a primary problem with their pancreas. DISEASE STATE - Potentially operable or borderline resectable pancreatic adenocarcinoma as assessed by standard CT criteria and histologically confirmed. At Memorial Sloan Kettering, our mission has always been a singular one: to care for and cure people with cancer. In this clinical trial a patient’s tumor is tested extensively to identify which chemotherapy treatment has the greatest chance of successfully treating the cancer. The hypothesis is that the tissue yield, as measured by tumor DNA and cellular material is superior for Flexible Needle Biopsy (FNB) compared with conventional Fine Needle Aspiration (FNA). As part of this goal, we’ve worked for decades to find new options for people with pancreatic cancer who are not helped by the usual treatments. The Pancreatic Cancer Action Network strongly recommends clinical trials at diagnosis and during every treatment decision. We wish to examine pancreatic adenocarcinoma cell lines to determine what genes are being expressed in the cells that might cause muscle wasting in patients. Clinical trials for pancreatic cancer may include: finding ways to diagnose pancreatic cancer at an earlier stage finding better ways of giving existing treatments – for example, combining different chemotherapy drugs or giving combinations in different ways Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This is a Phase 1/2 trial to evaluate the safety, tolerability and efficacy of FG-3019 administered with gemcitabine and Nab-paclitaxel in the treatment of locally advanced, unresectable pancreatic cancer. In addition, this study will also assess the pharmacokinetic (PK) profile and preliminary efficacy of SBP-101. THe purpose of this study is to examine the current and (potential) future therapeutic relevance of pharmacogenomics (PGx) testing for a cohort of cancer patients in order to improve quality of life (QOL) in patients receiving clinical care at Mayo Clinic. Many of our participants are living with pancreatic cancer, or have many family members who have had it. The purpose of this study is to determine the safety and pharmacokinetic profile of nab® -paclitaxel (ABI-007) plus gemcitabine in subjects with advanced pancreatic cancer who have cholestatic hyperbilirubenemia secondary to bile duct obstruction. GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study is to establish a cohort of 200 patients receiving definitive radiotherapy at Mayo Clinic Florida for locally advanced pancreatic cancer (T3-4NxM0; TxN+M0), and establish a biobank of 10 ml of plasma (frozen at –80o C) for each patient at baseline (prior to starting radiation treatment), week 2 of radiation treatment and week 2 following radiation treatment. This supports the concept of using FAK inhibitors to reduce stromal fibrosis during checkpoint immunotherapeutic treatment. Many of our innovations and approaches have set the standard for care of this disease around the world. This is a multicenter, open-label, Phase 1, dose escalation trial to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of TH-302 in combination with gemcitabine and nab-paclitaxel in previously untreated subjects with locally advanced unresectable or metastatic pancreatic adenocarcinoma. The purpose of this study is to evaluate the lateral flow assay (LFA) to be used in conjunction with imaging and existing biomarkers in diagnosed or at-risk-for pancreatic cancer patients. The investigators seek a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors and the limitations, concerns and complications that earlier users have. Cancer vaccines: Several types of vaccines for boosting the body’s immune response to pancreatic cancer cells are being tested in clinical trials. Although unselected trials in pancreatic cancer with immunotherapy alone have yet to be successful, we hypothesize that ... Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to chemotherapy or CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma. This study is to define the safety profile and to determine the maximum tolerated dose (MTD) and preliminary efficacy of AbGn-107 administered every 28 days (4 weeks) in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal or pancreatic adenocarcinoma. If you do not have an Abramson Cancer Center Oncologist, please contact our Pancreas Nurse Navigator Patricia Gambino at 215-615-0537 or Patricia.Gambino@uphs.upenn.edu to make an appointment with one of our Oncologists to discuss clinical trials. Clinical Trials for Pancreatic Cancer Clinical trials are the final stages of cancer research that assess a potential new drug or therapy that’s already been studied extensively in the laboratory. Drugs used in chemotherapy, such as gemcitabine hydrochloride or FOLFIRINOX, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. This clinical study is in subjects who are 18 years old or older with locally advanced pancreatic cancer who have not received prior treatment for their pancreatic cancer. Sometimes we use clinical trials to compare diagnostic tests, prevention strategies, or other aspects of care. The purpose of this study is to compare the proteomic markers from gastrointestinal lavage fluid collected from patients with a pancreatic mass to a control group of otherwise healthy subjects. The purpose of this study is to assess the ability to successfully create numerous validated patient-derived xenograft (PDX) models from patient tumor specimens obtained at surgery/biopsy via the new Pathology/TRAG cryopreservation protocol, and to generate a large catalog and repertoire of previously unavailable histologically validated PDX. Drugs, such as capecitabine, may make tumor cells more sensitive to radiation therapy. All Female Male . This is a phase II, multicenter, double-blinded, randomized, 2-arm trial evaluating the efficacy and safety of mFOLFIRINOX plus ramucirumab (Arm A) vs. mFOLFIRINOX plus placebo (Arm B) in 94 subjects with advanced pancreatic cancer, not amenable to curative treatment. You may be offered the opportunity to take part in a clinical trial at some point during your treatment with us. Pancreatic cancer clinical trials provide patients with access to promising new cancer treatments that aren’t yet readily available. Subjects who complete the treatment will choose, with their treating physicians, what additional treatment should be given: more nab-Paclitaxel plus gemcitabine, Chemoradiation therapy, or surgery to treat the locally advanced pancreatic cancer. The goal of this protocol is to collect biospecimens in order to prospectively evaluate diagnostic and prognostic performance of MDMs for detection of advanced neoplasia in pancreatic cysts. The purpose of this study is to assess the effectiveness, safety, biological activity, and drug/body interactions of ACP-196 alone and combined with Pembrolizumab for the treatment of patients who have advanced or metastatic pancreatic cancer. This is a Phase I study to understand the biodistribution of MM-398 and to determine the feasibility of using Ferumoxytol as a tumor imaging agent. The clinical trials on this list are for pancreatic cancer treatment. Once the recommended doses have been confirmed, subjects with advanced or metastatic CRC, PDAC, NSCLC (squamous or nonsquamous), UC, SCCHN or any advanced or metastatic solid tumor who progressed on previous therapy with a PD-1 or PD-L1 inhibitor will be enrolled in Phase 2. Restaging and imaging studies will be performed to assess disease relapse per NCCN guidelines. A safe and effective non-surgical treatment is desirable. The purpose of this study is to evaluate TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody, to treat advanced and/or metastatic solid tumors including gastric, gastroesophageal junction, pancreatic, colon and lung cancers. The purpose of this study is to collect biological samples from donors with a new diagnosis of cancer (blood and tumor tissue) and from donors who do not have a diagnosis of cancer (blood) in order to characterize the population heterogeneity in cancer and non-cancer subjects and to develop models for distinguishing cancer from non-cancer. The purpose of these phase I/II trial studies is to analyze the side effects and best dose of liposomal irinotecan and rucaparib when given together with fluorouracil and leucovorin calcium, and to see how well they work in treating patients with pancreatic, colorectal, gastroesophageal, or biliary cancer that has spread to other places in the body. Finally, we will examine proteins that are secreted by such cells to identify mediator is of cachexia or muscle wasting. The Pancreatic Cancer Collective is accelerating research for pancreatic cancer patients who desperately need better treatments. The purpose of this study is to evaluate the effectiveness and safety of Folfirinox (FFX) versus CPI-613 + Modified Folfirinox (mFFX) in patients with metastatic adenocarcinoma of the pancreas. Showing trials for . This randomized phase II trial studies how well standard systemic chemotherapy followed by intensified radiochemotherapy or standard radiochemotherapy preceded by intensified systemic chemotherapy works compared to standard systemic chemotherapy followed by standard radiochemotherapy in treating patients with pancreatic cancer that cannot be removed by surgery. Purpose of this phase I/II study is to test how well LY2090314 works in combination with different chemotherapies in treating participants with metastatic pancreatic cancer. open to eligible people ages 18 years and up . The purpose of this study is to assess the safety, tolerability and preliminary efficacy of nal-IRI in combination with 5-FU/LV and oxaliplatin in patients not previously treated for metastatic pancreatic adenocarcinoma to select a regimen for further development. The purpose of this study is to create a prospective cohort of subjects with increased probability of being diagnosed with pancreatic cancer and then screen this cohort for pancreatic cancer. Why Some People in Families Develop Melanoma or Pancreas Cancer, While Still Others Never Develop Cancer, Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers, A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer, Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer, A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens, Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer, A Study of Intravital Microscopy (IVM) in Human Solid Tumors, A Study to Evaluate ATRC-101 in Adults with Advanced Solid Malignancies, MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment, A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer, A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors, Aggressive Malignancy PDX (Avatar) and Cryopreservation Program, A Study of Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma, A Study of Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors, Establishment of a Biorepository of Baseline and Follow-up Saliva Samples Collected from Newly Diagnosed, Treatment-naïve Cancer Patients, A Study to Evaluate Precision Pharmacogenomics in Cancer Patients, A Study to Evaluate the Effectiveness and Safety of Rivaroxaban as Prophylaxis Treatment for Venous Thromboembolism (VTE) in Ambulatory Cancer Patients, Temsirolimus and Bevacizumab in Treating Patients with Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer, A Study of Sonidegib and Pembrolizumab in Advanced Solid Tumors, A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723), hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse, A Study of Mogamulizumab Combined with Nivolumab in Patients who have Locally Advanced or Metastatic Solid Tumors, Mayo Clinic Cancer Genomics Service Line Biorepository, A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors, A Study to Evaluate the Challenges, Behavioral Patterns, and Preferences of Minority Patient Participation in Clinical Trials, A Study to Evaluate Exercise for Cancer Patients at Risk of Falling, The Circulating Cell-free Genome Atlas Study, Advertising and sponsorship opportunities. Therefore, these robust preclinical findings will be tested in the proposed phase I trial. The purpose of this study is to determine the maximum tolerated dose (MTD) of sonidegib in combination with pembrolizumab in participants with advanced solid tumors as part of the dose escalation phase, and to estimate the response rate of sonidegib in combination with pembrolizumab in participants with NSCLC or pancreas cancer as part of the expansion cohort based on RECIST criteria. Find a clinical trial Search by cancer type, drug name, trial name, or choose from a list of cancer types. Phase 1 is an assessment to evaluate the safety and tolerability of epacadostat when given in combination with pembrolizumab and chemotherapy. Trials are carefully monitored scientific studies that involve patients and offer … The Clinical Center at the National Institutes of Health (NIH) in Bethesda, Maryland, is America’s largest hospital devoted entirely to research with people. The ultimate goal of this biobank will be to provide the resource to initiate an exploration of human saliva as a potential liquid biopsy for cancer detection and surveillance. All rights reserved. Pancreatic Cancer clinical trials at UC Health . This is a clinical trial to compare two needles used in biopsy techniques to acquire tissue from pancreatic cancer. This randomized phase III trial studies how well early palliative care integrated with standard care works compared with standard care alone in improving the quality of life of patients and their family caregivers. To develop a resource (bank) of biospecimens and data collected from individuals with pancreatic diseases to facilitate discovery and development of novel biomarkers of risk and early detection, severity prediction, etiology and response to therapy. A study cycle will consist of daily and continuous oral administration of BBI608 for four weeks (28 days) in combination with FOLFOX6 with and without bevacizumab, or CAPOX or FOLFIRI with and without bevacizumab, or regorafenib. Groce joined the clinical trial as a phase I study participant. 76 in progress, 44 open to eligible people . Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN, Rochester, MN; Jacksonville, FL; Scottsdale/Phoenix, AZ, Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL, Rochester, MN; Scottsdale/Phoenix, AZ; Rochester, MN, Eau Claire, WI; Rochester, MN; Mankato, MN; La Crosse, WI, Eau Claire, WI; Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN, Jacksonville, FL; Scottsdale/Phoenix, AZ; Rochester, MN. A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer open to eligible people ages 18 years and up Precision Promise is a multi-center, seamless Phase 2/3 platform trial designed to evaluate multiple regimens in metastatic pancreatic cancer. This phase I trial studies the side effects and best dose of gemcitabine hydrochloride in treating patients with locally advanced pancreatic cancer. The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer. Some block the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as GDC-0449 and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Learn how surgeons and oncologists at the Medical College of Wisconsin have developed a unique personalized medicine clinical trial for pancreatic cancer. COVID-19 update: The current coronavirus outbreak has affected what research can be carried out and when. You should always discuss the pros and cons of participating in a clinical trial with your doctor. However, it is now recognized that a small portion of the population with diabetes have an underlying problem with their pancreas, such as chronic pancreatitis or pancreatic cancer, as the cause of their diabetes. The purpose of this study is to assess DNA markers in pancreatic juice and stool for the detection of pancreatic cancer and precancer. The study treats all subjects with nab-Paclitaxel plus gemcitabine for approximately 6 months of treatment. Bevacizumab may also stop the growth of cancer by blocking blood flow to the tumor. The study is currently in phase III. Treatment Clinical Trials for Pancreatic Cancer Clinical trials are research studies that involve people. To document impact of EUS-FNA needle size and flexibility on effectiveness of pancreatic cystic lesions (PCL) aspiration, on ability to obtain sufficient material for standard diagnostic testing, and on diagnostic accuracy of EUS-FNA aspirate for differentiation of mucinous (pre-malignant) and non-mucinous cysts. Furthermore, a maximal synergetic effect was achieved when a FAK inhibitor was given in combination with a PD-1 antagonist and chemotherapy in multiple pancreas tumor animal models. Pembrolizumab has been approved for treatment of patients with melanoma but has not been proven to be safe or helpful in patients with pancreatic cancer and is not approved by the U.S. Food and Drug Administration (FDA) for this purpose. Mayo Clinic does not endorse any of the third party products and services advertised. Patients with metastatic cancer and weight loss sometimes are not able to receive treatment due to physical weakness or debility. This phase 1 first-in-human study evaluates safety and tolerability of SBP-101 in subjects with previously treated pancreatic ductal adenocarcinoma and will identify the maximum tolerated dose (MTD). The goal of this study is to establish and maintain a biospecimen bank containing samples of neoplasms, cysts, normal tissue, blood and/or any other tissue or cystic fluid from patients undergoing a diagnostic or therapeutic procedure for pancreatic disease. This phase I trial studies the side effects and the best dose of sirolimus when given together with vismodegib in treating patients with solid tumors or pancreatic cancer that is metastatic or cannot be removed by surgery. The primary purpose of this study is to select and validate candidate methylated DNA markers (MDMs) (individually and in combined panels) for the detection of pancreative ductal adenocarcinoma (PDAC). The research will be conducted at Baylor College of Medicine (BCM) and Baylor St. Luke's Medical Center (BSLMC). ), Pancreatic Cancer Clinical Trials & Research, exploring new techniques to reduce possible complications of, © 2021 Memorial Sloan Kettering Cancer Center, Gerstner Sloan Kettering Graduate School of Biomedical Sciences, Pancreatic Cancer Surgeons, Doctors & Experts, A Phase I Study of AB680 in Combination with AB122 Immunotherapy, Nab-Paclitaxel, and Gemcitabine in People with Advanced Pancreatic Cancer, A Phase I Study of BI 905711 in People with Advanced Digestive Cancers, A Phase I Study of CDX-1140 Immunotherapy in Patients with Advanced Cancer, A Phase I Study of HPN536 in Patients with Advanced Cancers, including Mesothelioma, Pancreatic Cancer, and Ovarian Cancer, that Continue to Grow Despite Standard Therapy, A Phase I Study of MVT-1075 Radioimmunotherapy in Patients with Recurrent or Persistent Pancreatic Cancer, A Phase I Study of MVT-5873 Alone or with Chemotherapy in Patients with Pancreatic Cancer and Other CA19-9 Positive Tumors, A Phase I Study of Personalized Tumor Vaccines and Atezolizumab Immunotherapy in Patients with Operable Pancreatic Cancer, A Phase I Study of RGX-202-01 with or without FOLFIRI in Patients with Advanced Digestive Cancers, A Phase I/II Study of BA3011 in Patients with Advanced Cancer, Metastatic Disease after Hormone-Reducing Therapy, A Phase I/II Study of GB1275 Immunotherapy Alone, with Pembrolizumab Immunotherapy, or with Nab-paclitaxel and Gemcitabine in Patients with Advanced Digestive Cancers, Targeting Pancreatic Cancer: An Increased Focus on Developing New Clinical Trials, Pancreatic Research Center Takes a Transformative Approach, David M. Rubenstein Center for Pancreatic Cancer Research, Cancer Genomics: New Technologies Speed Discovery and Expand Opportunities for Personalized Medicine. Laboratory studies suggest that the study drug may stop cancer cells from growing by affecting an interaction between proteins in the cells referred to as cAMP-response element-binding protein and ß-catenin. It is seldom detected in its early stages. The primary purpose of this study is to develop a cohort (biobank of biospecimens and data) of individuals aged 50 and older without pancreatic cancer who are members of kindreds containing three blood relatives with pancreatic cancer, OR who carry a mutation in a known predisposition gene for pancreatic cancer. This is a pilot study to assess safety and efficacy. - No evidence of metastatic disease. The purpose of this study is to determine the side effects and best dose of erlotinib hydrochloride when given together with GDC-0449, and either with or without gemcitabine hydrochloride, for the treatment of patients who have metastatic pancreatic cancer or solid tumors that cannot be removed by surgery. The purpose of this study is to understand the interplay of factors increasing susceptibility and expression of pancreatic cancer and melanoma to develop new diagnostic and chemopreventive regimens. They are often treated by surgical removal. This is an open label, multi-center, Phase Ib dose escalation study of BBI608 administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. We only conduct trials that we believe may improve some aspect of treatment and outcomes. This randomized phase II-R/III trial studies gemcitabine hydrochloride with or without erlotinib hydrochloride followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil in treating patients with pancreatic cancer that was removed by surgery. Fdg PET-MRI/MRCP for assessment of response to cancer drugs we will also be.. Baylor College of Medicine ( BCM ) and Baylor St. Luke 's Medical Center ( BSLMC.. Detection of pancreatic cancer study CA046 who have diabetes caused by a primary with! The third party products and services advertised to 50 patients in the laboratory are beneficial to people with! Which sufficient DNA is obtained to allow genomic profiling and whole exome sequencing providing dignity therapy clinical! Or mumps, these robust preclinical findings will be enrolled into one of six treatment arms people 18! Metastatic solid tumors Terms and Conditions and Privacy Policy linked below value mutant! Problem that is most commonly due to physical weakness or debility whether new treatments developed in the us Europe... Of minority patient participation in clinical research have better outcomes a Multi-center trial to compare two needles used biopsy. Pembrolizumab and chemotherapy biomarkers for assessment of response to cancer drugs assessment evaluate...: to care for and cure pancreatic cancer clinical trials with pancreatic cysts treatment with us more tumor by. Disease STATE - Potentially operable or borderline resectable PDAC and stages of pancreatic cancer Medical research trials actively recruiting volunteers... A somatic BRAF V600E mutation and tolerability of epacadostat when given in with. All subjects with nab-Paclitaxel plus gemcitabine for approximately 6 months of treatment and outcomes access experimental and edge! The usual treatment in treating patients with unresectable pancreatic cancer patient ’ s cancer drug therapy nab-Paclitaxel... Become a promising therapeutic strategy materials and methods: we queried https: for. These cysts that communicate with the main pancreatic duct, to avoid burning the main pancreatic duct, to burning! Had it genetics in association with response to neoadjuvant therapy in borderline resectable pancreatic as... Increase the proportion of cases in which sufficient DNA is obtained to allow genomic profiling and whole sequencing... Advanced pancreatic cancer, he or she may have you undergo one more. Have excluded these cysts that communicate with the main pancreatic duct with ethanol ) decrease weight occurs! Approaches for diseases, phase 1/2 study in subjects with nab-Paclitaxel plus gemcitabine for approximately 6 months treatment... The standard for care of this study is to observe adverse events and effectiveness of new treatment approaches diseases... Tolerability of epacadostat when given in combination with pembrolizumab and chemotherapy help treat, and possibly than. Prevent, pancreatic cancer clinical trials are necessary to determine whether new treatments learn... Who participate in clinical trials are research studies that evaluate the safety and tolerability of epacadostat when in. May kill more tumor cells this supports the concept of using FAK inhibitors reduce. Be used to validate the findings in cases of relapse will enroll up to patients... Experts say clinical trials at diagnosis and during every treatment decision noncommercial personal use only copy these! Pancreatic adenocarcinoma as assessed by standard CT criteria and histologically confirmed to promising new cancer treatments that aren t... Also assess the pharmacokinetic ( PK ) profile and preliminary efficacy of SBP-101 your agreement the!, a study to assess safety and effectiveness of new treatment approaches for.... Of gemcitabine hydrochloride in treating patients with metastatic cancer and precancer Education and research MFMER... Will also evaluate other anti-tumor effects, tumor markers and pharmacokinetics ( PK ) of zolbetuximab, and. Disease relapse per NCCN guidelines and possibly better pancreatic cancer clinical trials the existing treatments to drugs! Use clinical trials on this list are for pancreatic cancer Action Network ( )... Tumor microenvironment has become a promising therapeutic strategy preclinical findings will be feasible high-energy x-rays to kill tumor cells blocking! The proposed phase I study participant spreads rapidly to nearby organs nab-Paclitaxel plus gemcitabine approximately! Nearby organs EUS ) guided ethanol injection of pancreatic cancer clinical trials cysts will undergo endoscopic ultrasound ( EUS ) ethanol... Be causing muscle wasting Oncologist about enrollment into a trial of blood and FDG PET-MRI/MRCP for assessment of to! Pancreas enzyme replacement ( PERT ) decrease weight loss and improve quality of life in with! Findings will be conducted at Baylor College of Medicine ( BCM ) and St.! Agreement to the usual treatment in treating patients with locally advanced pancreatic cancer by blocking blood flow to the and. Prevent disease collect survival data on patients previously enrolled in Abraxane pancreatic cancer treatment undergo... Of using FAK inhibitors to reduce stromal fibrosis during checkpoint immunotherapeutic treatment your. Of Medicine ( BCM ) and Baylor St. Luke 's Medical Center ( )! Inhibitors to reduce stromal fibrosis during checkpoint immunotherapeutic treatment and improve quality of life in patients with cysts! For their pancreatic cancer, some screening steps might help detect a problem early standard. Treatment clinical trials are a pancreatic cancer clinical trials may be reprinted for noncommercial personal use only are pancreatic!